Nurix Therapeutics Ownership | Who Owns Nurix Therapeutics?


OverviewForecastRevenueFinancialsChart

Nurix Therapeutics Ownership Summary


Nurix Therapeutics is owned by 120.84% institutional investors, 1.43% insiders. Fmr is the largest institutional shareholder, holding 14.61% of NRIX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.01% of its assets in Nurix Therapeutics shares.

NRIX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockNurix Therapeutics120.84%1.43%-22.27%
SectorHealthcare Stocks 57.43%9.41%33.16%
IndustryBiotech Stocks 69.02%8.92%22.06%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr10.63M14.61%$200.35M
Blackrock6.82M12.42%$142.33M
Blackrock funding, inc. /de7.68M10.55%$144.61M
Vanguard group4.35M5.97%$81.86M
Redmile group4.19M5.76%$78.99M
Baker bros. advisors lp3.88M5.33%$73.14M
State street2.71M4.93%$56.53M
Wellington management group llp3.59M4.93%$67.57M
Price t rowe associates inc /md/3.01M4.13%$56.66M
Deep track capital, lp3.00M4.12%$56.52M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Redmile group4.19M5.50%$78.99M
Commodore capital lp3.00M4.14%$56.52M
Soleus capital management2.10M2.49%$39.62M
Affinity asset advisors940.08K2.37%$17.71M
Deep track capital, lp3.00M2.11%$56.52M
Velan capital investment management lp97.89K1.59%$1.84M
Parkman healthcare partners532.17K1.34%$10.03M
Opaleye management378.50K1.25%$7.13M
Westhill financial advisors228.33K0.96%$4.30M
Vienna powszechne towarzystwo emerytalne s.a. vienna insurance group85.00K0.93%$1.60M

Top Buyers

HolderShares% AssetsChange
Fmr10.63M0.01%10.05M
Blackrock6.82M0.00%2.24M
Commodore capital lp3.00M4.14%1.35M
Ra capital management1.33M0.33%1.33M
Driehaus capital management1.28M0.26%1.28M

Top Sellers

HolderShares% AssetsChange
Bain capital life sciences investors---1.13M
Deep track capital, lp3.00M2.11%-868.10K
Ark investment management1.53M0.24%-686.07K
Morgan stanley1.99M0.00%-541.10K
Candriam s.c.a.634.63K0.07%-427.33K

New Positions

HolderShares% AssetsChangeValue
Driehaus capital management1.28M0.26%1.28M$26.78M
Point72 asset management872.96K0.04%872.96K$16.45M
Perceptive advisors330.61K0.17%330.61K$6.23M
Norges bank318.80K0.00%318.80K$6.01M
Darwin global management163.68K0.29%163.68K$3.08M

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-9.00
True wealth design-15.00
Capital performance advisors llp-18.00
Lindbrook capital-19.00
Larson financial group-24.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 20241771.72%81,111,27120.04%1201.40%1039.57%47-16.07%
Sep 30, 2024174-1.14%67,568,4773.95%920.66%94-16.81%5624.44%
Jun 30, 202417524.11%64,997,07932.92%1181.49%11260.00%454.65%
Mar 31, 20241416.82%48,899,6246.46%891.25%702.94%4310.26%
Dec 31, 20231320.76%45,933,2032.43%841.24%6823.64%39-23.53%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv2.29M3.01%454.00
iShares Russell 2000 ETF1.83M2.42%-35.92K
ARK Genomic Revolution ETF1.63M2.14%-
T. Rowe Price New Horizons1.45M2.05%-
US Small-Cap Growth II Equity Comp1.45M2.05%-1.25K
ARK Genomic Revolution1.51M1.99%-691.71K
Fidelity Select Health Care1.36M1.79%75.76K
SPDR® S&P Biotech ETF1.24M1.64%9.40K
Fidelity Select Biotechnology1.14M1.50%-
T. Rowe Price Integrated US SmCapGrEq985.71K1.39%492.85K

Recent Insider Transactions


DateNameRoleActivityValue
Mar 03, 2025van Houte Hans Chief Financial OfficerSell$73.80K
Mar 03, 2025van Houte Hans Chief Financial OfficerSell$10.59K
Jan 31, 2025Ring Christine Chief Legal OfficerSell$2.05K
Jan 31, 2025Ring Christine Chief Legal OfficerSell$112.89K
Jan 30, 2025Ring Christine Chief Legal OfficerSell$5.91K

Insider Transactions Trends


DateBuySell
2025 Q1-11
2024 Q4-10
2024 Q3-13
2024 Q2-9
2024 Q1-4

NRIX Ownership FAQ


Who Owns Nurix Therapeutics?

Nurix Therapeutics shareholders are primarily institutional investors at 120.84%, followed by 1.43% insiders and -22.27% retail investors. The average institutional ownership in Nurix Therapeutics's industry, Biotech Stocks , is 69.02%, which Nurix Therapeutics exceeds.

Who owns the most shares of Nurix Therapeutics?

Nurix Therapeutics’s largest shareholders are Fmr (10.63M shares, 14.61%), Blackrock (6.82M shares, 12.42%), and Blackrock funding, inc. /de (7.68M shares, 10.55%). Together, they hold 37.58% of Nurix Therapeutics’s total shares outstanding.

Does Blackrock own Nurix Therapeutics?

Yes, BlackRock owns 12.42% of Nurix Therapeutics, totaling 6.82M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 142.33M$. In the last quarter, BlackRock increased its holdings by 2.24M shares, a 48.90% change.

Who is Nurix Therapeutics’s biggest shareholder by percentage of total assets invested?

Redmile group is Nurix Therapeutics’s biggest shareholder by percentage of total assets invested, with 5.50% of its assets in 4.19M Nurix Therapeutics shares, valued at 78.99M$.

Who is the top mutual fund holder of Nurix Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Nurix Therapeutics shares, with 3.01% of its total shares outstanding invested in 2.29M Nurix Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools